Skip to content
Clinical Trials – home
SwedenBack to Sweden

Clinical trials in Höllviken – page 20

1 391 clinical trials in Höllviken, Sweden. Every trial is listed in the EU Clinical Trials Register and updated daily.

SwedenOur site in SwedenKliniska-Provningar.se(opens in a new tab)
Höllviken at a glance
1 391
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 391 trials in Höllviken

Open in trial search

Study of dupilumab injections to reduce airway inflammation in adults aged 40-85 with chronic obstructive pulmonary disease

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of zoldonrasib with daraxonrasib, pembrolizumab and chemotherapy in patients with RAS G12D-mutant non-small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Revolution Medicines Inc.

Study of intravenous AOC 1001 to evaluate long-term safety and effectiveness in patients with myotonic dystrophy type 1

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:AOC 1001
  • Sponsor:Avidity Biosciences Inc.

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Takeda Development Center Americas Inc.

Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

Investigational
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Rilzabrutinib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Daiichi Sankyo Inc.

Study of Port Delivery System with ranibizumab given every 36 weeks in patients with neovascular age-related macular degeneration

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Evaluating sacituzumab tirumotecan alone or with pembrolizumab compared to standard treatment in untreated patients with metastatic triple-negative breast cancer with low PD-L1 expression

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International S.A.

Other cities in Sweden

The busiest research cities in the country

All 66 cities in Sweden

Clinical research in Höllviken

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) management through advanced combination therapy approaches. The studies aim to evaluate triple therapy effectiveness compared to dual bronchodilator treatments for improving cardiopulmonary outcomes.

  • Respiratory Disease Management
  • Cardiopulmonary Health
  • Therapeutic Combinations

These trials explore enhanced treatment options for patients with chronic respiratory conditions, focusing on improving their quality of life through optimized medication combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.